Quantcast

Latest Thyroid neoplasm Stories

2008-07-22 12:00:21

San Francisco-based biotech Exelixis has seen its shares rise after taking an investigational thyroid cancer drug into a Phase III trial. While the relatively low incidence of medullary thyroid cancer will limit the drug's commercial potential, the low barriers to market entry and high unmet need should help its chances of success, ultimately leading to a satisfactory return on development costs. The Phase III registrational trial is a randomized double-blind study evaluating XL184...

2008-07-21 12:01:26

Exelixis has initiated the Phase III registration trial of XL184 as a potential treatment for medullary thyroid cancer. The Phase III trial is a randomized, placebo-controlled, double-blinded study of XL184 as single-agent therapy in 315 patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Patients will be randomized in a 2:1 ratio to receive XL184 or placebo administered as a daily oral dose. The primary endpoint will be duration of...

2008-07-21 06:00:17

Exelixis, Inc. (Nasdaq:EXEL) announced today that the phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated. XL184 is a small molecule anticancer compound targeting the MET, RET, and VEGFR2 receptor tyrosine kinases. Recently, Exelixis and the U.S. Food and Drug Administration (FDA) reached agreement on the phase 3 registration trial via the Special Protocol Assessment process. Exelixis has also discussed the trial design with...

2008-07-17 03:00:12

WALTHAM, Mass., July 17, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from clinical trials with its vascular disrupting agent (VDA) product candidate, fosbretabulin (referred to as combretastatin A4-phosphate / CA4P), will be presented at the upcoming 7th International Conference on Head and Neck Cancer in San Francisco, CA, July...

2008-06-25 03:01:46

By Fisher, Ronald E Siegel, Barry A; Edell, Steven L; Oyesiku, Nelson M; Morgenstern, David E; Messmann, Richard A; Amato, Robert J ^sup 99m^Tc-EC20 is a folate receptor (FR)-targeted imaging agent consisting of the vitamin folate conjugated to ^sup 99m^Tc. FR is expressed on a variety of epithelial cancers, with advanced cancers often expressing FR at significantly higher levels than earlier stages of the disease. The goals of this pilot study were to determine the percentages of various...

2008-06-16 06:00:07

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the Special Protocol Assessment process. Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the phase 3 trial of XL184 as a potential...

248ba151cd92db3c1357ba18d4b825b91
2008-02-15 04:25:00

For years, doctors have hypothesized about a link between weight gain and cancers like breast and colon. A new European study published this week surmises that not only can weight gain increase risk for these types of cancer, but for many others as well, such as cancer of the thyroid, kidney, esophagus, uterus and gall bladder. Researchers covered more than 280,000 cases from North America, Europe, Asia, and Australia, in attempts to cover more ground than previous research. These cases...

2008-01-29 03:00:09

By Delikoukos, Stylianos Mantzos, Fotios Isolated thyroid gland injury due to blunt neck trauma is uncommon and rarely complicated by thyroid storm in patients without known hyperthyroidism. The aim of this study was to report our experience on blunt thyroid gland injury followed by massive gland hemorrhage, acute airway obstruction, and symptoms of thyroid storm. Among 231 patients with neck trauma, four patients appeared with isolated thyroid gland injury. In two of them, the diagnosis of...

2007-11-19 06:00:07

By Steve Sternberg and Anthony DeBarros BALTIMORE -- Soon after Holly Russell-Milstein took her thyroid cancer medicine at Johns Hopkins University here on Oct. 18, she went into self-imposed isolation in a row house a short walk from the hospital. The medicine, iodine 131, is a proven cancer fighter. But it's also radioactive, and in higher doses, can cause cancer. Russell-Milstein -- like thousands of other thyroid cancer patients in the USA each year -- worried that the radiation...

2007-07-01 03:16:18

By Furlan, Julio C Bedard, Yvan C; Rosen, Irving B This study examines the influence of tumor capsular invasion on the biological behavior of papillary (PTC) and follicular thyroid carcinoma (FTC) and the prognosis of surgically treated patients. This retrospective cohort study included 350 cases of PTC or FTC from a university teaching hospital. Patient charts were randomly selected and reviewed. The study population was divided into PTC and FTC groups. Each group was subdivided into CI+...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.